Stephen M. Simes, BioSante Pharmaceuticals President and CEO, To Present At Oppenheimer and Rodman & Renshaw Conferences
Tuesday November 4 at 9:20 am EST and Wednesday November 12 at 9:30 am EST
LINCOLNSHIRE, Illinois (October 31, 2008) – Stephen M. Simes, president and CEO of BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), will present at the Oppenheimer 19th Annual Healthcare Conference and the Rodman & Renshaw Annual Global Investment Conference, both in New York City.
Mr. Simes will discuss, on Tuesday November 4, 2008 at 9:20 am EST at the Oppenheimer Conference and on Wednesday November 12 at 9:30 am EST at the Rodman & Renshaw Conference, the LibiGel® (testosterone gel) clinical development plan and primary research data indicating the potential multi-billion dollar size of the U.S. market for BioSanteís LibiGel in the treatment of female sexual dysfunction. A live audio webcast of these presentations may be accessed at biosantepharma.cdmail.biz/Webcasts.php and a replay will be available at the same link.
“We are delighted to have the opportunity to participate at these healthcare conferences,” said Mr. Simes. “Notwithstanding current market conditions we look forward to improving the valuation of BioSante. Presenting to potential healthcare investors is part of our IR/PR efforts to help increase interest in BioSante.”
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S.
Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at: biosantepharma.cdmail.biz.
For more information please contact:
Harris D. McKinney, Inc.
The Investor Relations Group
Adam S. Holdsworth / Erica Ruderman
Laura Colontrelle /Janet Vasquez